文献速递放疗物理与技术姑息放疗与转移瘤

儿童临床试验中的放射治疗质量保证:六项QUARTET附属试验的首次报告

Radiotherapy quality assurance in paediatric clinical trials: first report from six QUARTET-affiliated trials.
PubMed 文献 · Radiother Oncol · 2023-02-23

该报告描述参与六项QUARTET附属试验的机构概况及个体病例审查(ICR)的初步结果。截至2022年10月31日,20个国家的66个站点获批,提交263例患者计划,完成254例ICR,拒收率39.8%,平均需1.4次提交才获批准,靶区勾画是最常见拒收原因。

要点

  • 截至2022年10月31日,20个国家共66个站点通过QUARTET站点审批。
  • 共完成254例ICR,拒收率39.8%,平均1.4次提交后获批。
  • 靶区勾画是ICR拒收最常见原因。

核心结论

  • QUARTET设施问卷是映射儿童和青少年放疗可用资源、人员与技术的宝贵工具。
  • 前瞻性ICR对儿童肿瘤临床试验至关重要,应优先开展以减少方案偏离。

研究设计与样本

  • 本报告为两部分分析:第一部分利用设施问卷、束流输出审计证书和先进技术认证记录构建获批机构概况;第二部分整理2022年10月31日前提交的ICR试验记录。
  • 纳入试验包括SIOPEN HR-NBL1、SIOPEN-LINES、SIOPEN-VERITAS、SIOP-BTG HRMB、EpSSG-FaR-RMS和SIOPEN HR-NBL2。

主要发现

  • 截至2022年10月31日,共103个机构启动QUARTET站点审批程序,20个国家的66个站点获批。
  • 参与机构常为儿科转诊站点,具备调强放疗或质子束治疗、指定的儿童放射肿瘤医师以及儿童适配设施和影像方案。
  • 共提交263例患者计划进行ICR,完成来自15个国家的254例ICR。
  • ICR拒收率为39.8%,平均需1.4次提交才获批准。
  • 靶区勾画是ICR拒收最常见原因。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: SIOP Europe's QUARTET project launched in 2016; aiming to improve access to high-quality radiotherapy for children and adolescents treated within clinical trials across Europe. The aim of this report is to present the profile of institutions participating in six QUARTET-affiliated trials and a description of the initial individual case review (ICR) outcomes. METHODS: This is a two-part analysis. Firstly, using facility questionnaires, beam output audit certificates, and advanced technique credentialing records to create a profile of approved institutions, and secondly, collating trial records for ICRs submitted prior to 31/10/2022. Trials included are: SIOPEN HR-NBL1, SIOPEN-LINES, SIOPEN- VERITAS, SIOP-BTG HRMB, EpSSG-FaR-RMS, and SIOPEN HR-NBL2. RESULTS: By 31/10/2022, a total of 103 institutions had commenced QUARTET site approval procedures to participate in QUARTET-affiliated trials; 66 sites across 20 countries were approved. These participating institutions were often paediatric referral sites with intensity modulated radiotherapy or proton beam therapy, designated paediatric radiation oncologists, and paediatric adapted facilities and imaging protocols available. In total, 263 patient plans were submitted for ICR, 254 ICRs from 15 countries were completed. ICRs had a rejection rate of 39.8%, taking an average of 1.4 submissions until approval was achieved. Target delineation was the most frequent reason for rejection. CONCLUSION: The QUARTET facility questionnaire is a valuable tool for mapping resources, personnel, and technology available to children and adolescents receiving radiotherapy. Prospective ICR is essential for paediatric oncology clinical trials and should be prioritised to reduce protocol violations.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Kelly SM, Turcas A, Corning C, et al. Radiotherapy quality assurance in paediatric clinical trials: first report from six QUARTET-affiliated trials. Radiother Oncol. 2023. PMID: 36828140. doi:10.1016/j.radonc.2023.109549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。